Oncolytic viruses (OVs) are a promising treatment for solid tumors. When injected into tumors, oncolytic viruses are able to selectively target cancer cells without affecting normal cells, causing cancer cell lysis byRead More…
Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases. Compared with other types of breast cancer, TNBC is more likely to spread, metastasize, and recur, and as itRead More…
Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases. Patients with this subtype typically have a poorer prognosis compared with other breast cancers, suggesting the need for improved existingRead More…
Today, pancreatic cancer remains one of the most lethal malignancies facing the global population. The 5-year survival rate for patients with pancreatic ductal adenocarcinoma (PDAC) is only about 3%, and PDAC isRead More…
Tumor-associated inflammation (TAI) is an important hallmark of all cancers and involves all cells in the tumor microenvironment (TME), which describes the entire spectrum of cancer cells, immune cells, endothelial cells, andRead More…
City of Hope, a world-renowned research and treatment organization for cancer, diabetes, and other life-threatening diseases, recently announced the initiation of a first-in-human clinical trial evaluating the use of an anti-cancer oncolyticRead More…
Oncolytic viruses (OVs) have emerged as a very attractive cancer treatment modality. OVs target cancer cells without affecting normal cells, causing cancer cell lysis by replicating within cancer cells and, at theRead More…
The 10th Annual Immuno-Oncology Summit was held in Boston during October 12-14, 2022. Creative Biolabs, as an exhibitor, successfully showcased at the 10th Annual Immuno-Oncology Summit at booth #9 and has attractedRead More…
As early as around 1800, doctors discovered that certain cancer patients would have their symptoms eased after being briefly infected with some viruses. Although the concept of using viruses to treat cancerRead More…
Oncolytic viruses have been proven to regulate the immune microenvironment, reduce suppressive immune phenotypes, and enhance anti-tumor immunity. Combining immune checkpoint inhibitors and oncolytic viruses is expected to overcome the resistance ofRead More…